Thursday, December 31, 2020

Shriram Transport Finance trades higher on raising Rs 240 crore through NCDs

Shriram Transport Finance is currently trading at Rs. 1041.65, up by 2.70 points or 0.26% from its previous closing of Rs. 1038.95 on the BSE.

The scrip opened at Rs. 1053.00 and has touched a high and low of Rs. 1053.00 and Rs. 1032.90 respectively. So far 30118 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1331.80 on 24-Feb-2020 and a 52 week low of Rs. 428.70 on 23-Mar-2020.


Last one week high and low of the scrip stood at Rs. 1055.30 and Rs. 998.85 respectively. The current market cap of the company is Rs. 26222.23 crore.

The promoters holding in the company stood at 26.48%, while Institutions and Non-Institutions held 64.91% and 8.60% respectively.

Shriram Transport Finance Company has raised Rs 240 crore through Senior, secured, rated, listed, redeemable, non convertible debentures (NCDs) and allotted 2400 Debenture having face value of Rs 10,00,000 each on private placement basis. The board of directors of the company at its meeting held on November 30, 2020 approved and allotted the same.

Shriram Transport Finance Company is a flagship company of the Chennai-based Shriram group and is classified as deposit taking Asset Financing NBFC.

Get watch our process Click here Ideal Stock Investment , daliy call profit, Market News, Fill Our ask an Expert form

Monday, December 28, 2020

UltraTech Cement gains on planning to raise Rs 1,000 crore via NCDs

Ultratech Cement is currently trading at Rs. 5090.00, up by 48.20 points or 0.96% from its previous closing of Rs. 5041.80 on the BSE.

The scrip opened at Rs. 5081.10 and has touched a high and low of Rs. 5098.00 and Rs. 5055.45 respectively. So far 2063 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 5257.90 on 09-Dec-2020 and a 52 week low of Rs. 2913.15 on 25-Mar-2020.


Last one week high and low of the scrip stood at Rs. 5188.05 and Rs. 4865.45 respectively. The current market cap of the company is Rs. 146660.74 crore.

The promoters holding in the company stood at 59.91%, while Institutions and Non-Institutions held 30.76% and 8.79% respectively.

UltraTech Cement is considering a proposal to raise funds by issuance of 10,000 rated, listed, non-convertible, redeemable, unsecured Non-convertible debentures(NCDs) of Rs 10,00,000 each aggregating to Rs 1,000 crore, on private placement basis, including the terms and conditions of the issue, on or after December 30, 2020. 

UltraTech Cement is the largest manufacturer of grey cement, ready mix concrete (RMC) and white cement in India.

Get watch our process Click here Ideal Stock Investment , daliy call profit, Market News, Fill Our ask an Expert form

Monday, December 21, 2020

Larsen & Toubro Infotech surges on eyeing significant share of UAE digital services market

Larsen & Toubro Infotech is currently trading at Rs. 3415.15, up by 63.75 points or 1.90% from its previous closing of Rs. 3351.40 on the BSE.

The scrip opened at Rs. 3384.00 and has touched a high and low of Rs. 3445.00 and Rs. 3363.40 respectively. So far 6304 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 3515.15 on 12-Oct-2020 and a 52 week low of Rs. 1207.60 on 19-Mar-2020.


Last one week high and low of the scrip stood at Rs. 3445.00 and Rs. 3215.50 respectively. The current market cap of the company is Rs. 59808.44 crore.

The promoters holding in the company stood at 74.36%, while Institutions and Non-Institutions held 17.62% and 8.02% respectively.

Larsen & Toubro Infotech (LTI), which extended an alliance with Abu Dhabi-based Injazat recently, is eyeing a significant share of the UAE digital services market to the tune of $ 200 million in six years of the partnership. In the first week of December, LTI extended its existing partnership with the UAE company under which it roll out a service delivery model.

LTI is a global technology consulting and digital solutions company helping more than 420 clients succeed in a converging world.

Get watch our process Click here Ideal Stock Investment , daliy call profit, Market News, Fill Our ask an Expert form

Friday, December 18, 2020

Axis Bank sticks to its caution script and so do its investors

In an update on its retail book, the private sector lender’s executives said delinquencies may spike in the third and fourth quarter of the current financial year

Axis Bank hasn't been able to bridge the valuation gap even with the sector index in a sign that investors share the bank’s caution


Things may get worse before they get better. That, in a nutshell, seems to be the message from Axis Bank’s management.

In an update on its retail book through a media interaction, the private sector lender’s executives said delinquencies may spike in the third and fourth quarter of the current financial year. To be sure, the lender has reported a sharp improvement in collections, just like its peers. Collection efficiency surged to 95% after the moratorium ended in August and gross bad loans were down to 4.18% of total loan book for the September quarter.

But the commentary from the management has been more cautious than that of rivals such as HDFC Bank and ICICI Bank. Even in Thursday’s media interaction, the management stuck to caution. The bank is right in its guarded approach. Economic indicators have been mixed, with some sectors still showing pain. Employment and wages have taken a huge hit and the recovery in both is patchy. The Reserve Bank of India’s (RBI's) consumer sentiment survey has shown that Indians remain pessimistic over future employment and income prospects. “Given the fact that a lot of people lost their jobs, some had to take salary cuts and some industries were badly affected, these will have some impact on delinquency and portfolio collections," said Sumit Bali, head of retail lending at Axis Bank at Thursday’s interaction.

Small businesses continue to remain under stress, and asset quality here is only propped up due to the government’s guarantee schemes and regulatory forbearance. Once they are removed, it would be challenging for lenders to maintain current asset quality metrics. Analysts have pointed out that bad loans in the micro, small and medium enterprises (MSMEs) loan book may increase in coming quarters.

That is not to say that Axis Bank sees pain even in FY22. In fact, the lender has stressed that asset quality metrics may see improvement in the next financial year. Most of its peers, too, have indicated the same and the recent rally in banking shares show that investors share this optimism.

Axis Bank’s shares, too, have rallied in tandem with others in the past three months. However, the stock has underperformed peers such as ICICI Bank and HDFC Bank since January. It has not been able to bridge the valuation gap even with the sector index. Perhaps this is a sign that investors share the bank’s caution.

Get watch our process Click here Ideal Stock Investment, daliy call profit, Market News, Fill Our ask an Expert form

Tuesday, December 01, 2020

Dr. Reddy’s Lab gains on entering into definitive agreement with Glenmark Pharmaceuticals

Dr. Reddys Laboratories is currently trading at Rs. 4839.65, up by 10.05 points or 0.21% from its previous closing of Rs. 4829.60 on the BSE.

The scrip opened at Rs. 4861.15 and has touched a high and low of Rs. 4868.00 and Rs. 4820.05 respectively. So far 6001 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5514.65 on 21-Sep-2020 and a 52 week low of Rs. 2497.60 on 19-Mar-2020. 


Last one week high and low of the scrip stood at Rs. 5018.70 and Rs. 4673.90 respectively. The current market cap of the company is Rs. 80309.00 crore.

The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.50% and 15.66% respectively.

Dr. Reddy’s Laboratories has entered into a definitive agreement with Glenmark Pharmaceuticals to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along-with rights to the trademarks, dossiers and patents for the territories mentioned.

The acquired brands represent two types of products i.e mometasone mono product and combination of mometasone with azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Watch our Stock Market Target Calls Quality, Track sheet – Click Here or Subscribe us for Stock Market Trading >>>> Stock Cash Tips

Yes Bank at Rs 11 or Rs 30? Here's the stock outlook after 50% rally in two months

  Market experts expect that both investors to bring in vast experience and expertise in the financial domain to handhold Yes Bank for its n...